Introduction {#sec1-1}
============

Acne is a common skin disease, affecting approximately 85% of adults. The increased secretion of sebum, the follicular hyperkeratosis, the presence of *Propionibacterium acnes* and inflammatory response are the four major factors in the acne pathogenesis \[[@ref1]\]. Currently, isotretinoin is the only drug that targets all the causative factors of acne. This medicament is also effective in acne cases unsuccessfully treated with other therapeutic agents. However, isotretinoin results in some side effects including dry skin cracked lips, erythema and rashes.

Antihistamines H1 have been used for a long time to treat pruritus and allergic conditions. Recently, they have also been used in acne treatment because of their ability to reduce sebum and side effects created by isotretinoin \[[@ref2]\]. Some studies also mention the effect of antihistamines in reducing inflammation and preventing acne scars.

In Vietnam, there has been no evaluation study done on the use of antihistamines in acne treatment.

This study aimed to evaluate the efficacy of oral isotretinoin used alone and in combination with desloratadine in the treatment of moderate acne vulgaris.

Methods {#sec1-2}
=======

A comparative clinical trial on 62 moderate acne vulgaris patients was conducted at the National Hospital of Dermatology and Venereology, from August 2017 to August 2018.

A group of 62 patients were randomised into 2 equal groups: studied group and control group.

Both groups were treated with isotretinoin 20mg per day in 16 weeks. The combined treatment was 5mg desloratadine daily in 16 weeks for the studied group.

For the evaluation, we counted the number of acne lesions, scoring GAGS (Global Acne Grading System), recording unwanted effects after 2, 4, 8, 12 and 16 weeks of treatment.

Evaluation of acne outbreak during treatment was based on the appearance of new nodules at each re-examination. We used a scale of no outbreak (no new lesion), mild outbreak (\< 5 nodules), moderate outbreak (5-10 nodules) and severe outbreak (≥ 10 nodules).

The evaluation of clinical efficacy after 16 weeks of treatment was scaled of:

\- Excellent: no inflammation and non-inflammation lesions.- Good: reduced by ≥ 90% of the number of lesions.- Fair: reduced by ≥ 75-90% of the number of lesions.- Moderate: reduced by ≥ 50-75% of the number of lesions.- Poor: reduced by \<50% of the number of lesions.

Results {#sec1-3}
=======

General characteristics of the included objects {#sec2-1}
-----------------------------------------------

At the initiation time of treatment, the two groups had similar characteristics regarding patient gender, age, average illness duration, number of lesions, illness severity and isotretinoin dose, as presented in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of patients in both groups before treatment

  Indicator                               Studied group (n = 31)   Control group (n = 31)   p           
  --------------------------------------- ------------------------ ------------------------ ----------- -----------
  Sex                                     Male (n)                 11                       12          p = 0,074
  Female (n)                              20                       19                                   
  Mean age (years)                        21,90 ± 4,1              22.06 ± 4.20             p = 0.88    
  Mean duration of disease (months)       38,74 ± 34,44            43.16 ± 26.62            p = 0.55    
  Mean weight (kg)                        52,32 ± 8,56             57.61 ± 9.90             p = 0.186   
  The number of inflammatory lesion       20,29 ± 1,94             19.58 ± 8.60             p = 0.172   
  The number of non-inflammatory lesion   48,90 ± 29,36            47.87 ± 25.44            p = 0.345   
  Total no of lesions                     68,87 ± 35,86            68.45 ± 28.95            P = 0.182   
  Mean GAGS score                         22,90 ± 3,11             22.77 ± 3.03             p = 0.869   

Treatment results {#sec2-2}
-----------------

### Change in the number of inflammatory lesions {#sec3-1}

In the studied group, the number of inflammatory lesions was significantly lower than that in the control group, with p \< 0.025 as shown in [Figure 1](#F1){ref-type="fig"}.
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### Change in the illness severity score {#sec3-2}

An illness severity score of the studied group was significantly lower than that in the control group from week 4 onwards with p \< 0.05 as shown in [Table 2](#T2){ref-type="table"}.

###### 

Change in the illness severity score

  Time      Studied group   Control group   p
  --------- --------------- --------------- -------
  Week 0    22.9 ± 3.11     22.77 ± 3.03    0.869
  Week 2    20.5 ± 4.22     21.45 ± 4.31    0.388
  Week 4    17.11 ± 4.22    19.35 ± 4.70    0.06
  Week 8    13.78 ± 5.48    15.03 ± 4.11    0.025
  Week 12   8.44 ± 5.40     12.03 ± 4.27    0.007
  Week 16   3.71 ± 3.81     6.52 ± 4.35     0.015

### Treatment efficacy after 16 weeks {#sec3-3}

The studied group had 45.2% of acne resolved, higher than that in the control group: 22.6%, with p \< 0.05 as shown in [Figure 2](#F2){ref-type="fig"}.

![Treatment efficacy after 16 weeks](OAMJMS-7-217-g002){#F2}

Unwanted effects {#sec2-3}
----------------

### Acne outbreak {#sec3-4}

The studied group had a significantly lower outbreak rate than that in the control group with p \< 0.05 at week 2 and 4. At week 16, both groups had no outbreaks.

![26 years old female from the studied group (Isotretinoin + Desloratadine)](OAMJMS-7-217-g003){#F3}

### Other unwanted effects {#sec3-5}

At the time of follow-up, both groups experienced side effects such as dried skin, dried lips, itching. In the studied group, the rate of itching was significantly lower than the control group (week 2: 12.9%; week 4: 6.2% versus 64.5% in week 2 and 71% in week 4). There was no difference between the two groups regarding side effects such as dried lips, dried skin, flaking and blushing.

Discussion {#sec1-4}
==========

Studies have shown that inflammation in acne starts very early, even before the appearance of the lesion and continues at all stages of acne lesion development \[[@ref3]\]. Acne inflammation response is due to the release of inflammatory mediators such as histamine and leukotrienes. Therefore, the use of antihistamines can effectively prevent the formation of new acne lesions and have a significant impact on resolving the old acne lesions. In our study, the average number of inflammatory lesions in the studied group was significantly lower than that in the group using only isotretinoin. The reason probably is the combination of anti-inflammatory effects of both retinoids and antihistamines. However, we did not find any difference in the reduction of non-inflammatory lesions between the two groups.

![24 years-old female from the control group (Isotretinoin)](OAMJMS-7-217-g004){#F4}

After 16 weeks, the mean GAGS score in the studied group was lower than in the control group (3.71 ± 3.81 vs 6.52 ± 4.35), with p = 0.015. In Lee's study, the reduction of GAGS scores in the studied group was seen from week 2. However, the significant difference was just from week 4 onwards \[[@ref2]\]. Yosef's study showed similar results \[[@ref4]\].

After 16 weeks of treatment, both groups had good outputs: the studied group achieved 45.2% excellent, 35.5% good, and remaining 19.3% fair; the results in the control group were 22.6%, 29%, and 49.1% average response, respectively. However, our results showed that the desloratadine group was better (p \< 0.05). Experimental studies have shown that desloratadine inhibits inflammatory mediators including IL-4, IL-6, IL-8, IL-13, prostaglandins, leukotriene, tryptase and histamine \[[@ref5]\]. Thus, desloratadine acts as an anti-inflammatory role. Also, desloratadine also reduces the formation of squalene, an important component of the sebum \[[@ref6]\], \[[@ref7]\]. In Lee's study, the studied group had 40% of cases clear, 50% improvement while the control group had 20% of patients clear, 40% improvement \[[@ref2]\]. Studies by Dhaher SA and Jasim ZM showed the same results of 50% excellent result, 39.5% good results in the studied group while control group were 31.6% excellent, 34.2% good, 26.3% average and 7.9% poor \[[@ref8]\].

Acne outbreaks are common side effects after starting treatment with isotretinoin for 2-4 weeks. The mechanism of the outbreak is unclear, but it is related to the release of *P. acnes and sebaceous gland* antigens, enhancing the inflammatory response \[[@ref9]\]. In our study, the anti-inflammatory effect of antihistamines may have resulted in mild outbreak rate of the studied group: 22.6% at week 2, 16.1 % at week 4, that were lower than those in control group (45.2% and 38.7%, respectively). Similar results were seen in Lee's study \[[@ref2]\].

In our study, the itching was less common in the studied group, attributed to the effects of desloratadine.

In conclusion, treating moderate acne vulgaris with oral isotretinoin in combination with antihistamines enhances the curative effectiveness and reduces side effects of itching and acne outbreaks, that is linked with oral isotretinoin intake.
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